In October 2026, Volaris increased its available seat miles (ASM) by 7.7% year-over-year, driven by a 27.5% growth in international capacity, which now represents half of its total capacity. The airline launched five new U.S.–Mexico routes, leading to a 21.7% rise in international revenue passenger miles (RPMs), despite an 8.4% decline in domestic RPMs. Total passengers transported reached 2.6 million, with a slight dip in overall load factor to 82.4% due to new route ramp-up. Volaris focuses on profitable growth by aligning capacity with demand and expanding its international footprint, aiming for stronger unit revenues.
Regarding Volaris' October 2026 traffic results, here is Pluang's market snapshot as of Nov 06, 2026 20:41 WIB: Among 134 Consumer Cyclical-sector US stocks tradable on Pluang, 40 rose and 90 fell today. Notable movers include Under Armour Inc Class A (UA) down 9.95% at USD 4.84 with a typical hold time of 22 days, Under Armour Inc Class A (UAA) down 9.73% at USD 5.01 with 100% sell order activity, and Allbirds Inc (BIRD) up 9.23% at USD 1.42 with 100% sell order activity.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
